The global hypertension drug market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of hypertension and rising awareness about the disease. The major players in this market are AstraZeneca, Novartis, Pfizer, Sanofi-Aventis, Eli Lilly and Company, Merck & Co., Inc, Boehringer Ingelheim GmbH & Co. KG and others.
Some Of The Growth Factors Of This Market:
- The aging population is a major factor in the growth of the hypertension drug market.
- The increasing prevalence of obesity and diabetes are also factors in the growth of this market.
- The increase in chronic kidney disease is another factor that will contribute to the growth of this market, as these patients are at risk for developing hypertension and other cardiovascular diseases, which can lead to an increased need for treatment with antihypertensive drugs.
- Increasing awareness about hypertension and its consequences will also contribute to the growth of this market, as it will lead to more people being diagnosed with high blood pressure and subsequently treated with antihypertensive drugs such as ACE inhibitors, beta blockers, calcium channel blockers or diuretics.
- Advances in drug development may also contribute to the growth of this market by providing new treatments for hypertension.
Industry Growth Insights published a new data on “Hypertension Drug Market”. The research report is titled “Hypertension Drug Market research by Types (Calcium Channel Blockers, Diuretics, Beta Blockers Vasodilators, Angiotensin Converting Enzyme Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Renin Inhibitors), By Applications (Hospital, Private clinic, Others), By Players/Companies Lupin Limited, Novartis AG, Daiichi - Sankyo, Pfizer Inc, Ranbaxy Laboratories Limited, Sanofi S.A, AstraZeneca Plc, Johnson & Johnson Ltd, Boehringer Ingelheim, Merck & Co.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hypertension Drug Market Research Report
By Type
Calcium Channel Blockers, Diuretics, Beta Blockers Vasodilators, Angiotensin Converting Enzyme Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Renin Inhibitors
By Application
Hospital, Private clinic, Others
By Companies
Lupin Limited, Novartis AG, Daiichi - Sankyo, Pfizer Inc, Ranbaxy Laboratories Limited, Sanofi S.A, AstraZeneca Plc, Johnson & Johnson Ltd, Boehringer Ingelheim, Merck & Co.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Hypertension Drug Market Report Segments:
The global Hypertension Drug market is segmented on the basis of:
Types
Calcium Channel Blockers, Diuretics, Beta Blockers Vasodilators, Angiotensin Converting Enzyme Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Renin Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Private clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lupin Limited
- Novartis AG
- Daiichi - Sankyo
- Pfizer Inc
- Ranbaxy Laboratories Limited
- Sanofi S.A
- AstraZeneca Plc
- Johnson & Johnson Ltd
- Boehringer Ingelheim
- Merck & Co.
Highlights of The Hypertension Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Calcium Channel Blockers
- Diuretics
- Beta Blockers Vasodilators
- Angiotensin Converting Enzyme Inhibitors
- Alpha Blockers
- Angiotensin Receptor Blockers
- Renin Inhibitors
- By Application:
- Hospital
- Private clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hypertension Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hypertension drug is a medication used to lower blood pressure.
Some of the key players operating in the hypertension drug market are Lupin Limited, Novartis AG, Daiichi - Sankyo, Pfizer Inc, Ranbaxy Laboratories Limited, Sanofi S.A, AstraZeneca Plc, Johnson & Johnson Ltd, Boehringer Ingelheim, Merck & Co..
The hypertension drug market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hypertension Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hypertension Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hypertension Drug Market - Supply Chain
4.5. Global Hypertension Drug Market Forecast
4.5.1. Hypertension Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hypertension Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hypertension Drug Market Absolute $ Opportunity
5. Global Hypertension Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hypertension Drug Market Size and Volume Forecast by Type
5.3.1. Calcium Channel Blockers
5.3.2. Diuretics
5.3.3. Beta Blockers Vasodilators
5.3.4. Angiotensin Converting Enzyme Inhibitors
5.3.5. Alpha Blockers
5.3.6. Angiotensin Receptor Blockers
5.3.7. Renin Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hypertension Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hypertension Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Private clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hypertension Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hypertension Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hypertension Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hypertension Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hypertension Drug Demand Share Forecast, 2019-2026
9. North America Hypertension Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hypertension Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hypertension Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Private clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hypertension Drug Market Size and Volume Forecast by Type
9.7.1. Calcium Channel Blockers
9.7.2. Diuretics
9.7.3. Beta Blockers Vasodilators
9.7.4. Angiotensin Converting Enzyme Inhibitors
9.7.5. Alpha Blockers
9.7.6. Angiotensin Receptor Blockers
9.7.7. Renin Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hypertension Drug Demand Share Forecast, 2019-2026
10. Latin America Hypertension Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hypertension Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hypertension Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Private clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hypertension Drug Market Size and Volume Forecast by Type
10.7.1. Calcium Channel Blockers
10.7.2. Diuretics
10.7.3. Beta Blockers Vasodilators
10.7.4. Angiotensin Converting Enzyme Inhibitors
10.7.5. Alpha Blockers
10.7.6. Angiotensin Receptor Blockers
10.7.7. Renin Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hypertension Drug Demand Share Forecast, 2019-2026
11. Europe Hypertension Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hypertension Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hypertension Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Private clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hypertension Drug Market Size and Volume Forecast by Type
11.7.1. Calcium Channel Blockers
11.7.2. Diuretics
11.7.3. Beta Blockers Vasodilators
11.7.4. Angiotensin Converting Enzyme Inhibitors
11.7.5. Alpha Blockers
11.7.6. Angiotensin eceptor Blockers
11.7.7. Renin Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hypertension Drug Demand Share, 2019-2026
12. Asia Pacific Hypertension Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hypertension Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hypertension Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Private clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hypertension Drug Market Size and Volume Forecast by Type
12.7.1. Calcium Channel Blockers
12.7.2. Diuretics
12.7.3. Beta Blockers Vasodilators
12.7.4. Angiotensin Converting Enzyme Inhibitors
12.7.5. Alpha Blockers
12.7.6. Angiotensin Receptor Blockers
12.7.7. Renin Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hypertension Drug Demand Share, 2019-2026
13. Middle East & Africa Hypertension Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hypertension Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hypertension Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Private clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hypertension Drug Market Size and Volume Forecast by Type
13.7.1. Calcium Channel Blockers
13.7.2. Diuretics
13.7.3. Beta Blockers Vasodilators
13.7.4. Angiotensin Converting Enzyme Inhibitors
13.7.5. Alpha Blockers
13.7.6. Angiotensin Receptor Blockers
13.7.7. Renin Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hypertension Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hypertension Drug Market: Market Share Analysis
14.2. Hypertension Drug Distributors and Customers
14.3. Hypertension Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Lupin Limited
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis AG
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Daiichi - Sankyo
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Ranbaxy Laboratories Limited
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi S.A
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AstraZeneca Plc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Johnson & Johnson Ltd
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Boehringer Ingelheim
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Merck & Co.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook